- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 21, Issue 3, 2020
Current Drug Targets - Volume 21, Issue 3, 2020
Volume 21, Issue 3, 2020
-
-
TNF-α and IL-6: The Link between Immune and Bone System
Authors: Tiantian Wang and Chengqi HeOsteoimmunology is a new subject which focuses on the communication between the immune and the skeletal systems. Both the immune system and bone communicate with each other. Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) play important roles in immune responses and bone metabolism. TNF-α and IL-6 enhance macrophage activation and antigen presentation, Read More
-
-
-
Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors
Authors: Yanan Li, Qingrong Dong, Ting Mei, Meichen Zheng, Ramasamy R. Kumar, Bin Yu, Chunsheng Wu, Hui Zhang and Feifei AnThe RAS-RAF-MEK-ERK signaling pathway (MAPK signaling) is hyperactivated in more than 30% of human cancers. The abnormal activation of this pathway is mainly due to the gain-offunction mutations in RAS or RAF genes. Furthermore, the crucial roles of mitogen-activated protein kinase kinase (MEK) in tumorigenesis, cell proliferation and apoptosis inhibition, make MEK inhibitors (MEKi) attractive candidates for the target Read More
-
-
-
Role of Adenosine Kinase Inhibitor in Adenosine Augmentation Therapy for Epilepsy: A Potential Novel Drug for Epilepsy
Authors: Xiongfei Wang and Tianfu LiEpilepsy, an ancient disease, is defined as an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological, and social consequences of this condition. Antiepileptic drugs (AEDs) are currently used as first-line treatment for patients with epilepsy; however, around 36% of patients are diagnosed with refractory epilepsy, which means two or more AEDs have been considere Read More
-
-
-
Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer
Authors: Ashish R. Dwivedi, Amandeep Thakur, Vijay Kumar, Ira Skvortsova and Vinod KumarResistance to chemotherapy and relapse are major hurdles for the effective treatment of cancer. Major reason for this is a small sub population of cancer stem cells (CSCs) and its microenvironment. CSCs are critical driving force for several types of cancer, such as gastric, colon, breast and many more. Hence, for the complete eradication of cancer, it is necessary to develop therapeutic approaches that can specifically targe Read More
-
-
-
Urea Transporters Identified as Novel Diuretic Drug Targets
Authors: Min Li, Shun Zhang and Baoxue YangBackground: Urea Transporters are a family of membrane channel proteins that facilitate the passive transport of urea across the plasma membrane. UTs are divided into two subgroups, UT-A and UT-B. UT-As are primarily located in renal tubule epithelia and UT-Bs are highly expressed in renal descending vasa recta and extrarenal multiple tissues. Various urea transporter knockout mice exhibit low urine concentrating a Read More
-
-
-
The Therapeutic Potential of Chemokines in the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Authors: Lin Zhou, Luyao Ao, Yunyi Yan, Wanting Li, Anqi Ye, Yahui Hu, Weirong Fang and Yunman LiBackground: Some of the current challenges and complications of cancer therapy are chemotherapy- induced peripheral neuropathy (CIPN) and the neuropathic pain that are associated with this condition. Many major chemotherapeutic agents can cause neurotoxicity, significantly modulate the immune system and are always accompanied by various adverse effects. Recent evidence suggests that cross-talk occurs between t Read More
-
-
-
Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014
More LessHSP90 is a member of the family of heat shock proteins responsible for folding proteins into mature conformations and thus maintaining their biological function in cells. Since it is involved in all hallmarks of cancer, HSP90 has been considered as a promising drug target for cancer therapy. Eighteen HSP90 inhibitors have entered clinical trials, however, none has been approved by the FDA. There is still a great need for novel Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
